Global Doxorubicin Market Size, by Drug Formulation (Lyophilized Powder, Doxorubicin Injection), by Application (Bladder Cancer, Leukemia, Breast Cancer) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1012235
  • |
  • Publishe Date : August 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Doxorubicin market was estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Developing countries are disproportionately affected by the growing numbers of cancers due to growing and aging populations. Hence, the increasing number of cancer cases and the increasing need to treat them effectively and efficiently is going to help boost the market for doxorubicin in the forecast period. However, side effects associated with the drug will hamper the market growth in forecast period.

The global doxorubicin market is primarily segmented based on different drug formulations, applications, and regions.

On the basis of drug formulation, the market is split into:
* Lyophilized Powder
* Doxorubicin Injection

On the basis of application, the market is divided into:
* Bladder Cancer
* Leukemia
* Breast Cancer
* Lymphoma
* Other Application

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Sun Pharmaceutical Industries Ltd
* Pfizer, Inc.
* Cipla, Inc.
* Cadila Pharmaceuticals
* SRS Pharmaceuticals Pvt. Ltd
* Janssen Products, LP
* Teva Pharmaceutical Industries Ltd.
* MicroBiopharm Japan Co., Ltd.,
* Synbias Pharma
* Boryung

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, drug formulation and application market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions drug formulation and application with qualitative and quantitative information and facts

Target Audience:
* Doxorubicins Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Doxorubicin Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Doxorubicin Market - Porter\'s Five Forces Analysis
4.4. Global Doxorubicin Market - PESTEL Analysis

5. Global Doxorubicin Market, by Drug Formulation
5.1. Global Doxorubicin Market, Size and Forecast, 2015-2026
5.2. Global Doxorubicin Market, by Lyophilized Powder, 2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Doxorubicin Market, by Doxorubicin Injection, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026

6. Global Doxorubicin Market, by Application
6.1. Global Doxorubicin Market, Size and Forecast, 2015-2026
6.2. Global Doxorubicin Market, for Bladder Cancer, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Doxorubicin Market, for Leukemia, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Doxorubicin Market, for Lymphoma, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026
6.5. Global Doxorubicin Market, for Breast cancer, 2015-2026
6.5.1. Key driving factors, trends and opportunities
6.5.2. Market size and forecast, 2015-2026

7. Global Doxorubicin Market, by Region
7.1. Doxorubicin Market Regional Analysis, 2015-2026
7.2. Global Doxorubicin Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Doxorubicin Market, 2015-2026
7.3.1. North America Doxorubicin Market Size and Forecast, 2015-2026
7.3.2. North America Doxorubicin Market by Country, 2015-2026
7.3.2.1. U.S. Doxorubicin Market, 2015-2026
7.3.2.2. Canada Doxorubicin Market, 2015-2026
7.4. Europe Doxorubicin Market, 2015-2026
7.4.1. Europe Doxorubicin Market Size and Forecast, 2015-2026
7.4.2. Europe Doxorubicin Market by Country, 2015-2026
7.4.2.1. Germany Doxorubicin Market, 2015-2026
7.4.2.2. France Doxorubicin Market, 2015-2026
7.4.2.3. Italy Doxorubicin Market, 2015-2026
7.4.2.4. UK Doxorubicin Market, 2015-2026
7.4.2.5. Spain Doxorubicin Market, 2015-2026
7.4.2.6. Rest of Europe Doxorubicin Market, 2015-2026
7.5. Asia Pacific Doxorubicin Market, 2015-2026
7.5.1. Asia Pacific Doxorubicin Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Doxorubicin Market by Country, 2015-2026
7.5.2.1. Japan Doxorubicin Market, 2015-2026
7.5.2.2. China Doxorubicin Market, 2015-2026
7.5.2.3. India Doxorubicin Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Doxorubicin Market, 2015-2026
7.6. South America Doxorubicin Market, 2015-2026
7.6.1. South America Doxorubicin Market Size and Forecast, 2015-2026
7.6.2. South America Doxorubicin Market by Country, 2015-2026
7.6.2.1. Mexico Doxorubicin Market, 2015-2026
7.6.2.2. Brazil Doxorubicin Market, 2015-2026
7.6.2.3. Rest of South America Doxorubicin Market, 2015-2026
7.7. Middle East & Africa Doxorubicin Market, 2015-2026
7.7.1. Middle East & Africa Doxorubicin Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Doxorubicin Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Doxorubicin Market, 2015-2026
7.7.2.2. South Africa Doxorubicin Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Doxorubicin Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2019

9. Company Profiles
9.1. Pfizer Inc.
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Johnson & Johnson Services, Inc.
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Sun Pharmaceutical Industries Ltd.
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Meiji Seika Pharma Co., Ltd
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Teva Pharmaceutical Industries Ltd.
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. MicroBiopharm Japan Co., Ltd.
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. Synbias Pharma
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Boryung
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Janssen Products, LP
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. SRS Pharmaceuticals Pvt. Ltd
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type